Dilated cardiomyopathy (DCM) is defined by left ventricular dilation and systolic dysfunction not explained by abnormal loading or coronary disease. Management increasingly blends genetic precision with the modern heart-failure toolkit — though disease-specific therapy for genetic subtypes has proved harder to achieve than hoped.
Genetics and precision medicine
About 40% of familial DCM has an identifiable genetic cause, and next-generation sequencing has improved detection and opened the door to genotype-guided care. Genotype matters for prognosis and management — certain variants (LMNA, and the arrhythmogenic genes) carry elevated arrhythmic risk that influences defibrillator decisions independent of ejection fraction.
Pharmacological therapy
Guideline-directed heart-failure therapy remains foundational: beta-blockers, ACE inhibitors or ARBs (or an ARNI), and mineralocorticoid receptor antagonists. SGLT2 inhibitors are now an established fourth pillar of heart failure with reduced ejection fraction and are also of mechanistic interest for direct effects on myocardial energetics and stiffness. Notably, registry data show DCM patients tend to achieve better uptake of guideline-directed therapy and better outcomes than patients with ischemic cardiomyopathy (a lower adjusted risk of death or heart-failure hospitalization).
Imaging
Cardiac MRI, particularly with late gadolinium enhancement, is central to early diagnosis, precise phenotyping, and risk stratification — the presence and pattern of fibrosis helps identify patients at higher arrhythmic risk.
Emerging and gene-directed therapy — with a realistic caveat
Gene- and RNA-based therapies aimed at correcting specific mutations are under investigation, but the field has had a sobering result: the Phase 3 REALM-DCM trial of the p38α inhibitor ARRY-371797 for LMNA-related DCM was terminated for futility, and its development was discontinued. LMNA-related DCM therefore remains a genuine unmet need, and genotype-specific disease modification in DCM is still aspirational rather than available. Several novel small molecules and gene-targeted approaches remain in earlier-stage development.
Further reading: genetics of DCM (Eldemire et al., Annual Review of Medicine 2023); pathophysiology and precision medicine (Gigli et al., Nature Reviews Cardiology 2025); REALM-DCM (Garcia-Pavia et al., Circulation: Heart Failure 2024, terminated for futility); advances in genetic cardiomyopathies (Parikh et al., Cell 2025).